

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

Final Stakeholder list

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|---|---|
| Company | General |
| CSL Behring (garadacimab) | All Wales Therapeutics and Toxicology Centre |
| Patient/carer groups | Allied Health Professionals Federation |
| Action for Children | Board of Community Health Councils in |
| Allergy UK | Wales |
| Anaphylaxis UK | British National Formulary |
| Asthma and Lung UK | Care Quality Commission |
| Genetic Alliance UK | Cell and Gene Therapy Catapult |
| HAE UK | Department of Health, Social Services |
| Immunodeficiency UK | and Public Safety for Northern Ireland |
| Jnetics | Healthcare Improvement Scotland |
| NARA - The Breathing Charity | Hospital Information Services – |
| National Children's Bureau | Jehovah's Witnesses |
| South Asian Health Foundation | Medicines and Healthcare products |
| Specialised Healthcare Alliance | Regulatory Agency |
| UK Primary Immune-deficiency | National Association of Primary Care |
| Patient Support Charity (UKPIPS) | National Pharmacy Association NHS Alliance |
| Healthcare professional groups | NHS Alliance NHS Confederation |
| Association for Respiratory | Scottish Medicines Consortium |
| Technology and Physiology | Welsh Government |
| Association of Genetic Nurses & | Weish Government Weish Health Specialised Services |
| Counsellors | Committee |
| Association of Paediatric Emergency | Committee |
| Medicine | Comparator companies |
| British Geriatrics Society | BioCryst Pharmaceuticals (berotralstat) |
| British Paediatric Allergy, Immunity | CSL Behring (Berinert) |
| and Infection Group (BPAIIG) | Maxwellia (tranexamic acid) |
| British Paediatric Respiratory Society | • Mylan (tranexamic acid) |
| British Skin Foundation | Pharming Group N.V (Ruconest) |
| British Society for Allergy & Clinical | Rivopharm (tranexamic acid) |
| Immunology | Sovereign Medical (tranexamic acid) |
| British Society for Gene and Cell | Takeda (Cinryze, lanadelumab) |
| Therapy | • Tillomed Laboratories (tranexamic acid) |
| British Society for Genetic Medicine | . , , , |

Final stakeholder list for the evaluation of garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] Issue date: September 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.




| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|--|
| British Society for Haematology British Society for Immunology British Thoracic Society BSI Clinical Immunology Professional Network (BSI-CIPN) ILD-IN: Interstitial Lung Diseases Interdisciplinary Network Immunology and Allergy Nurses Group National Heart and Lung Institute Neonatal and Paediatric Pharmacists Group Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Paediatrics & Child Health Royal College of Paediatrics & Child Health Royal College of Physicians Royal College of Physicians Royal Society of Medicine Royal Society of Medicine Royal Society of Medicine - Allergy and Immunology Section UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders Others Department of Health and Social Care NHS England | Submit of appeal) Relevant research groups Asthma, Allergy and Inflammation Research Trust British Association for Lung Research Cochrane Airways Group Cochrane UK David Hide Asthma and Allergy Research Centre Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Final stakeholder list for the evaluation of garadacimab for preventing recurrent attacks of hereditary
angioedema in people 12 years and over [ID6394]
Issue date: September 2024© National Institute for Health and Care Excellence 2024. All rights reserved.2 of 3



Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.